By Rita Duran | Green Vibes Weekly | March 2026 The cannabis industry is standing at the edge of what could be its most transformative moment—and yet, nothing has officially changed. As of March 2026, cannabis remains classified as a Schedule I substance under federal law. However, mounting pressure on the
News
Blue Dream tops U.S. cannabis sales in 2025–2026, dominating with balanced effects, sweet berry flavor, and consistent consumer demand.
California
For years, California’s cannabis industry sold a dream: scale fast, grow louder, and ride the wave of legalization toward limitless upside. Venture capital poured in. Brands multiplied. Delivery platforms promised frictionless access. The mood was euphoric—part counterculture, part tech boom. That era is ending. What’s taking its
News
New York’s legal cannabis market crossed a symbolic threshold in 2025: it became big. After a halting and often criticized rollout in its early years, the state’s adult-use cannabis industry posted its strongest growth to date, with licensed dispensaries expanding rapidly across the five boroughs and beyond. Cumulative
News
The United States is at a pivotal moment in cannabis policy. After decades of federal prohibition, the government is moving forward with a process that could reclassify cannabis from Schedule I—reserved for substances deemed to have no accepted medical use—to Schedule III, a category that acknowledges medical value